DARÉ Bioscience
About DARÉ Bioscience
Daré Bioscience is a clinical-stage pharmaceutical company advancing products for women’s reproductive health. Women’s reproductive health encompasses a broad spectrum of categories, many of which have unmet needs. Daré is committed to developing a portfolio that expands options, improves outcomes, and enhances safety for women.YEAR FOUNDED:
2015
LEADERSHIP:
Founder & CEO: Sabrina Martucci Johnson
CFO & CBO: Lisa Walters-Hoffert
VP, Projects and Operations: Mark Walters
Board Member: Roger Hawley
165 articles about DARÉ Bioscience
-
Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023
8/3/2023
Daré Bioscience, Inc., a leader in women’s health innovation, announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 10, 2023, to review its financial results for the quarter ended June 30, 2023 and to provide a Company update.
-
Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth
7/31/2023
Daré Bioscience, Inc. today announced it was awarded a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH) in the amount of approximately $385,000 to support activities related to the conduct and completion of proof-of-concept target validation studies in support of a potential new approach for the prevention and treatment of idiopathic preterm birth.
-
Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems
7/11/2023
Daré Bioscience, Inc. (NASDAQ: DARE) today announced that the company’s Chief Scientific Officer, David Friend, Ph.D., will present during the Novel Drug Delivery Technologies, Systems and Devices section of the 9th Annual International Symposium of Drug Delivery Systems being held July 12-14, 2023, in Amsterdam, the Netherlands.
-
Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women
7/11/2023
Daré Bioscience, Inc. today announced additional positive data from the exploratory Phase 2b RESPOND study evaluating topical Sildenafil Cream, 3.6% (Sildenafil Cream) as a treatment for female sexual arousal disorder (FSAD).
-
Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
7/6/2023
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a virtual Key Opinion Leader (KOL) webinar on Tuesday, July 11, 2023, at 4:30 p.m. EDT.
-
Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel
7/5/2023
Daré Bioscience, Inc. today reaffirmed its commitment to the commercial launch of XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% with collaborator Organon (NYSE: OGN), and announced that Organon will pay Daré $1.0 million in July 2023.
-
Daré Bioscience Announces Publication in Menopause
6/21/2023
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication in Menopause.
-
Daré Bioscience to Present at the Maxim Group Virtual Healthcare Conference
6/14/2023
Daré Bioscience, Inc., a leader in women’s health innovation, announced that Sabrina Martucci Johnson, the company’s President and CEO, will present at the Healthcare Virtual Conference presented by Maxim Group LLC and hosted by M-Vest, being held June 20 – 22, 2023.
-
Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1
6/9/2023
Daré Bioscience, Inc. today announced the publication of results of its Phase 1/2 clinical study of DARE-VVA1, a proprietary, investigational formulation of tamoxifen for intravaginal administration to treat vulvovaginal atrophy (VVA) in women without the use of hormones.
-
Daré Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
6/5/2023
Daré Bioscience, Inc. (NASDAQ: DARE) and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced positive topline data from the exploratory Phase 2b RESPOND study evaluating topical Sildenafil Cream, 3.6% (Sildenafil Cream) as a treatment for female sexual arousal disorder (FSAD).
-
Daré Bioscience to Participate in Two Upcoming Conferences: 2023 BIO International Convention and the Longwood Healthcare Leaders Spring 2023 MIT Conference
6/1/2023
Daré Bioscience, Inc., a leader in women’s health innovation, announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two conferences during the week of June 5th:
-
Daré Bioscience Announces Availability of Publication on the Patient-Centered Concept Elicitation Study for Female Sexual Arousal Disorder in The Journal of Sexual Medicine
5/31/2023
Daré Bioscience, Inc., a leader in women’s health innovation, announced the publication of results of the patient-centered study designed to elucidate the commonly reported symptoms, including severity of symptoms, associated with female sexual arousal disorder.
-
Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update
5/11/2023
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended March 31, 2023 and provided a company update.
-
Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023
5/4/2023
Daré Bioscience, Inc. today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 11, 2023, to review its financial results for the quarter ended March 31, 2023 and to provide a Company update.
-
Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%
4/20/2023
Daré Bioscience, Inc. (NASDAQ: DARE) and Strategic Science & Technologies, LLC (SST) today announced initiation of screening and enrollment for a Phase 1 clinical study using thermography to assess the pharmacodynamic and pharmacokinetic characterization of Sildenafil Cream, 3.6% (Sildenafil Cream), a late-stage product candidate being developed as a potential new treatment for female sexual arousal disorder (FSAD).
-
David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, Inc., to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany
4/19/2023
Daré Bioscience, Inc., a leader in women’s health innovation, announced that the company’s Chief Scientific Officer, David Friend, Ph.D., will be presenting in the Keynote Forum of the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany.
-
Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therapy
4/18/2023
Daré Bioscience, Inc. today announced that Climacteric , the official journal of the International Menopause Society, published safety and acceptability results from a Phase 1 clinical trial of DARE-HRT1.
-
Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference
4/17/2023
Daré Bioscience, Inc. announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a panel discussion at the Innovations in Women’s Health Business Conference, hosted by Xpectives.Health, on April 20, 2023 at Westin Copley Place, Boston, MA.
-
Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update
3/30/2023
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2022 and provided a company update.
-
Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023
3/23/2023
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 30, 2023, to review its financial results for the year ended December 31, 2022 and to provide a Company update.